{"entity":"vertex-pharmaceuticals","id":"ent_vertex-pharmaceuticals","name":"Vertex Pharmaceuticals","wikidata":"Q2744099","page":"https://asof.is/record/vertex-pharmaceuticals","summary":"Vertex Pharmaceuticals is an American pharmaceutical company, headquartered in Boston. It reported revenue of $11.02B for the period ended December 31, 2024.","title":"Vertex Pharmaceuticals: revenue $11.02B","key_facts":[{"label":"Headquarters","value":"Boston","claim":"clm_A5822A229828"},{"label":"Revenue","value":"$11.02B","recorded":"11,020,100,000 United States dollar","note":"to 2024-12-31","claim":"clm_9011721F7C0D"},{"label":"Ticker","value":"VRTX · Nasdaq","claim":"clm_725C8AE3FDC6"}],"faq":[{"question":"Where is Vertex Pharmaceuticals headquartered?","answer":"Boston."},{"question":"What is Vertex Pharmaceuticals's revenue?","answer":"$11.02B for the period ended December 31, 2024."}],"as_of":"2025-11-10","known_by":null,"since":null,"fact_pages":[{"predicate":"headquarters","page":"https://asof.is/record/vertex-pharmaceuticals/headquarters","md":"https://asof.is/record/vertex-pharmaceuticals/headquarters.md","json":"https://asof.is/v1/entities/vertex-pharmaceuticals/headquarters"},{"predicate":"revenue","page":"https://asof.is/record/vertex-pharmaceuticals/revenue","md":"https://asof.is/record/vertex-pharmaceuticals/revenue.md","json":"https://asof.is/v1/entities/vertex-pharmaceuticals/revenue"},{"predicate":"net_income","page":"https://asof.is/record/vertex-pharmaceuticals/net_income","md":"https://asof.is/record/vertex-pharmaceuticals/net_income.md","json":"https://asof.is/v1/entities/vertex-pharmaceuticals/net_income"},{"predicate":"operating_income","page":"https://asof.is/record/vertex-pharmaceuticals/operating_income","md":"https://asof.is/record/vertex-pharmaceuticals/operating_income.md","json":"https://asof.is/v1/entities/vertex-pharmaceuticals/operating_income"},{"predicate":"quarterly_revenue","page":"https://asof.is/record/vertex-pharmaceuticals/quarterly_revenue","md":"https://asof.is/record/vertex-pharmaceuticals/quarterly_revenue.md","json":"https://asof.is/v1/entities/vertex-pharmaceuticals/quarterly_revenue"}],"products":[],"coverage":{"entity":"vertex-pharmaceuticals","name":"Vertex Pharmaceuticals","kind":"organization","sources":[{"source":"wikidata","item":"Q2744099","covers":"dated statements whose reference URL is the source: leadership, ownership, names, founding, headquarters; never financial figures"},{"source":"wikidata-products","covers":"products it makes, develops or publishes, as released claims, when the release date cites a reference URL; a rotating scan, a few dozen entities a run"},{"source":"sec","cik":875320,"ticker":"VRTX","covers":"annual and quarterly figures from XBRL, registrant name, tickers and fiscal year end; officer and director changes (8-K Item 5.02) and material events (other 8-K items)"}],"holds":{"claims":553,"open":22,"retracted":0,"first":"2007-12-31","predicates":{"quarterly_operating_income":{"claims":54,"open":1,"kind":"fact"},"total_assets":{"claims":68,"open":1,"kind":"fact"},"total_equity":{"claims":70,"open":1,"kind":"fact"},"quarterly_revenue":{"claims":54,"open":1,"kind":"fact"},"shares_outstanding":{"claims":67,"open":1,"kind":"fact"},"quarterly_research_and_development":{"claims":40,"open":1,"kind":"fact"},"operating_income":{"claims":18,"open":1,"kind":"fact"},"revenue":{"claims":18,"open":1,"kind":"fact"},"research_and_development":{"claims":14,"open":1,"kind":"fact"},"cash_and_equivalents":{"claims":73,"open":1,"kind":"fact"},"quarterly_net_income":{"claims":50,"open":1,"kind":"fact"},"net_income":{"claims":17,"open":1,"kind":"fact"},"agreement":{"claims":2,"open":2,"kind":"event"},"state_of_incorporation":{"claims":1,"open":1,"kind":"identifier"},"sic_industry":{"claims":1,"open":1,"kind":"identifier"},"ticker":{"claims":1,"open":1,"kind":"identifier"},"fiscal_year_end":{"claims":1,"open":1,"kind":"identifier"},"headquarters":{"claims":1,"open":1,"kind":"fact"},"listed_on":{"claims":1,"open":1,"kind":"fact"},"registrant_name":{"claims":1,"open":1,"kind":"fact"},"cik":{"claims":1,"open":1,"kind":"identifier"}}},"freshness":[{"origin":"sec","label":"SEC EDGAR filings: XBRL figures, registry fields, 8-K officer changes and events (sec_ingest.py, sec_officers.py, sec_events.py)","claims":553,"last_added":"2026-11-08","last_checked":"2026-11-09","last_verified":null}],"gaps":["ceo: none public; unknown, not absent: a claim is published only once checked against its source","posts: no official feed speaks for it (pipeline/feeds.json primary_for); what it holds comes from Wikidata, filings and other publishers' feeds"],"group":[],"group_complete":true,"rule":"sources: what the pipeline reads for this entity, from its config (pipeline/entities.json, feeds.json, sec_companies.json, huggingface_authors.json). holds: its public claims by predicate; open is held today; kind fact is what entity_state answers by default, event is for timeline. freshness, per ingest (origin): last_added is the day it last put a new claim here (first_seen_at), last_checked the day one was last checked against its source (checked_on), last_verified the day reverify.py last confirmed one against Wikidata (value_json.verified_at). Only checked claims are public, so a fact missing here is unknown, not absent. gaps: what the record does not cover for this entity, so an empty answer is not read as news."},"claims":[{"id":"clm_4B154EA0AEAE","predicate":"agreement","value":"Alpine Immune Sciences, Inc.","valid_from":"2024-04-10","valid_to":null,"published":"2024-04-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals agreement: Alpine Immune Sciences, Inc.\", as of 2024-04-10. Claim clm_4B154EA0AEAE, https://asof.is/claim/clm_4B154EA0AEAE, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000119312524092475/0001193125-24-092475-index.htm.","url":"https://asof.is/claim/clm_4B154EA0AEAE","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000119312524092475/0001193125-24-092475-index.htm","tier":"primary","publisher":"SEC EDGAR 8-K","published_at":"2024-04-11T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-09","quote":"On April 10, 2024, Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (“ Parent ”), Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Merger Sub ”), and Alpine Immune Sciences, Inc., a Delaware corporation (the “ Company ”), entered into","url":"https://www.sec.gov/Archives/edgar/data/875320/000119312524092475/0001193125-24-092475-index.htm"}},{"id":"clm_2FB43E38D7CC","predicate":"cash_and_equivalents","value":"4,939,600,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 4,939,600,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_2FB43E38D7CC, https://asof.is/claim/clm_2FB43E38D7CC, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm.","url":"https://asof.is/claim/clm_2FB43E38D7CC","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B4475729CD2A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_E8D76EDFB1A2","predicate":"cik","value":"0000875320","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cik: 0000875320\", undated. Claim clm_E8D76EDFB1A2, https://asof.is/claim/clm_E8D76EDFB1A2, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320.","url":"https://asof.is/claim/clm_E8D76EDFB1A2","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_7E8737D65987","predicate":"fiscal_year_end","value":"12-31","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals fiscal year end: 12-31\", undated. Claim clm_7E8737D65987, https://asof.is/claim/clm_7E8737D65987, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320.","url":"https://asof.is/claim/clm_7E8737D65987","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_A5822A229828","predicate":"headquarters","value":"Boston","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals headquarters: Boston\", undated. Claim clm_A5822A229828, https://asof.is/claim/clm_A5822A229828, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320.","url":"https://asof.is/claim/clm_A5822A229828","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_B527C44C89E1","predicate":"listed_on","value":"Nasdaq","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals listed on: Nasdaq\", undated. Claim clm_B527C44C89E1, https://asof.is/claim/clm_B527C44C89E1, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320.","url":"https://asof.is/claim/clm_B527C44C89E1","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_B3A7B0C585DF","predicate":"net_income","value":"-535,600,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals net income: -535,600,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_B3A7B0C585DF, https://asof.is/claim/clm_B3A7B0C585DF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000053/0000875320-25-000053-index.htm.","url":"https://asof.is/claim/clm_B3A7B0C585DF","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_406C31565DD9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000053/0000875320-25-000053-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2024, filed 2025-02-13"}},{"id":"clm_33A4466539E6","predicate":"operating_income","value":"-232,900,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals operating income: -232,900,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_33A4466539E6, https://asof.is/claim/clm_33A4466539E6, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000053/0000875320-25-000053-index.htm.","url":"https://asof.is/claim/clm_33A4466539E6","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_08B6F6FEE28A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000053/0000875320-25-000053-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2024, filed 2025-02-13"}},{"id":"clm_2FE795B3AF8B","predicate":"quarterly_net_income","value":"1,082,900,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: 1,082,900,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_2FE795B3AF8B, https://asof.is/claim/clm_2FE795B3AF8B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm.","url":"https://asof.is/claim/clm_2FE795B3AF8B","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_58ABF4712193","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_7EF8A5505C22","predicate":"quarterly_operating_income","value":"1,186,200,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: 1,186,200,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_7EF8A5505C22, https://asof.is/claim/clm_7EF8A5505C22, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm.","url":"https://asof.is/claim/clm_7EF8A5505C22","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B8F364B1BB32","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_CF81367A05A7","predicate":"quarterly_research_and_development","value":"603,100,000 United States dollar","valid_from":"2022-03-31","valid_to":null,"published":"2022-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly research and development: 603,100,000 United States dollar\", as of 2022-03-31. Claim clm_CF81367A05A7, https://asof.is/claim/clm_CF81367A05A7, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532022000014/0000875320-22-000014-index.htm.","url":"https://asof.is/claim/clm_CF81367A05A7","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000014/0000875320-22-000014-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2022","published_at":"2022-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2022, filed 2022-05-06"}},{"id":"clm_8AB184162D82","predicate":"quarterly_revenue","value":"3,076,400,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 3,076,400,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_8AB184162D82, https://asof.is/claim/clm_8AB184162D82, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm.","url":"https://asof.is/claim/clm_8AB184162D82","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_78B1FE0A2ECC","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_E5A558D9CC9E","predicate":"registrant_name","value":"VERTEX PHARMACEUTICALS INC / MA","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals registrant name: VERTEX PHARMACEUTICALS INC / MA\", undated. Claim clm_E5A558D9CC9E, https://asof.is/claim/clm_E5A558D9CC9E, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320.","url":"https://asof.is/claim/clm_E5A558D9CC9E","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_A31B2D7AAD7A","predicate":"research_and_development","value":"3,051,100,000 United States dollar","valid_from":"2021-12-31","valid_to":null,"published":"2022-02-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals research and development: 3,051,100,000 United States dollar\", as of 2021-12-31. Claim clm_A31B2D7AAD7A, https://asof.is/claim/clm_A31B2D7AAD7A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532022000007/0000875320-22-000007-index.htm.","url":"https://asof.is/claim/clm_A31B2D7AAD7A","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000007/0000875320-22-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2021","published_at":"2022-02-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2021, filed 2022-02-09"}},{"id":"clm_9011721F7C0D","predicate":"revenue","value":"11,020,100,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals revenue: 11,020,100,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_9011721F7C0D, https://asof.is/claim/clm_9011721F7C0D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000053/0000875320-25-000053-index.htm.","url":"https://asof.is/claim/clm_9011721F7C0D","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B151EC07FDAE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000053/0000875320-25-000053-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2024, filed 2025-02-13"}},{"id":"clm_663C199EF289","predicate":"shares_outstanding","value":"253,718,831 shares","valid_from":"2025-10-31","valid_to":"2026-02-06","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 253,718,831 shares\", as of 2025-10-31 (until 2026-02-06). Claim clm_663C199EF289, https://asof.is/claim/clm_663C199EF289, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm.","url":"https://asof.is/claim/clm_663C199EF289","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B7B98F7F000A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_572849379A15","predicate":"sic_industry","value":"Pharmaceutical Preparations (2834)","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals sic industry: Pharmaceutical Preparations (2834)\", undated. Claim clm_572849379A15, https://asof.is/claim/clm_572849379A15, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320.","url":"https://asof.is/claim/clm_572849379A15","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_2D9EFA2C2469","predicate":"state_of_incorporation","value":"MA","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals state of incorporation: MA\", undated. Claim clm_2D9EFA2C2469, https://asof.is/claim/clm_2D9EFA2C2469, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320.","url":"https://asof.is/claim/clm_2D9EFA2C2469","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_725C8AE3FDC6","predicate":"ticker","value":"VRTX","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals ticker: VRTX\", undated. Claim clm_725C8AE3FDC6, https://asof.is/claim/clm_725C8AE3FDC6, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320.","url":"https://asof.is/claim/clm_725C8AE3FDC6","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_D95598CEB876","predicate":"total_assets","value":"24,862,300,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 24,862,300,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_D95598CEB876, https://asof.is/claim/clm_D95598CEB876, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm.","url":"https://asof.is/claim/clm_D95598CEB876","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0090178AE4A5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_1E5EC8CA7B8E","predicate":"total_equity","value":"17,318,800,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 17,318,800,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_1E5EC8CA7B8E, https://asof.is/claim/clm_1E5EC8CA7B8E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm.","url":"https://asof.is/claim/clm_1E5EC8CA7B8E","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_335F6E7CE9CE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2025, filed 2025-11-04"}}],"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{},"checked_by":{"page-read":"its source page states the value and the date","sec-filing":"parsed from the SEC filing"}}}